🔄 Reverse Merger & IP Structuring Memo
Expanded preliminary Big 4-style issue framework for Tehiru Aerial Systems.
This memo frames the corporate restructuring ("flip") into a U.S. parent structure, with the central focus on IP migration risk — not the mechanics of the reverse merger itself. The preferred baseline keeps a U.S. C-Corp parent over an Israeli operating subsidiary, with legacy Israeli IP staying in Israel.
🇺🇸 U.S. INC (Parent)
🇮🇱 Israel LTD (Subsidiary)
U.S. parent over Israeli subsidiary — no legacy IP transfer in the baseline structure.
⭐ Executive Recommendation
Recommended baseline: Do not transfer legacy Israeli IP to the U.S. entity now unless there is a clear commercial reason, a valuation has been prepared, Israeli tax cost has been modeled, and counsel has confirmed that the transaction will not unintentionally trigger Israeli exit tax, Innovation Authority restrictions, or other adverse results.
The cleaner path remains a U.S. parent / Israeli subsidiary structure:
- Use a U.S. C-Corp parent, usually Delaware, as the fundraising and investment-facing company.
- Keep the Israeli company alive as Israel OpCo and owner of historical Israeli-developed IP.
- Document new U.S.-created IP prospectively so that U.S. ownership is supported by facts, agreements, payroll/consulting records, and technical development evidence.
- Have the Israeli entity provide R&D or support services to the U.S. parent under arm's-length transfer-pricing arrangements.
- Preserve U.S. investor QSBS planning where possible, but avoid overpromising QSBS status for founder shares or existing Israeli SAFE holders without a dedicated U.S. tax analysis.
- Evaluate whether the Israeli company can qualify for, or preserve, Preferred Technological Enterprise benefits under the Law for the Encouragement of Capital Investments.
- Adopt a U.S. equity incentive plan only after obtaining a 409A valuation for the U.S. company and coordinating Israeli tax treatment for any Israeli service providers.
1. Current Fact Pattern
2. Strategic Tax Objectives
- Avoid an actual or deemed transfer of legacy Israeli IP unless the tax cost is known and acceptable.
- Create a U.S. parent structure that is familiar to U.S. investors and can support future U.S. fundraising.
- Preserve the potential for U.S. QSBS treatment for eligible investors in the U.S. company.
- Maintain defensible transfer-pricing positions between the U.S. parent and Israeli subsidiary.
- Evaluate whether Israeli PTE benefits make it tax-efficient to keep Israeli-developed IP in Israel.
- Use valuation tools, including DLOM where appropriate, but only with a well-supported independent valuation.
- Set up a compliant U.S. option plan using a valid 409A valuation before granting options.
3. Main Issue: IP Migration, Not the Corporate Reverse Merger
A share-level reorganization or flip into a U.S. parent can often be implemented more cleanly than an asset transfer, especially where there is a single founder, limited investors, and no active U.S. operations. The key tax issue is whether the steps cause, or can be characterized as causing, a sale, contribution, license, migration, or functional relocation of Israeli-developed IP.
If historical Israeli IP is moved to the U.S. entity, Israeli tax authorities may treat the transaction as a taxable disposition or exit event. The valuation of early-stage technology IP can be highly judgmental, and a tax authority may argue that most of the company's enterprise value resides in Israeli-created intangibles, know-how, software, designs, trade secrets, engineering history, data, and embedded technical capability.
🚩 Separate Red Flag — Governmental / Grant Restrictions
Whether the Israeli company received grants, funding, approvals, or support from the Israel Innovation Authority, Ministry of Defense, universities, customers, or strategic partners. Any such rights can restrict transfer, licensing, commercialization, or foreign ownership of know-how.
4. Preferred Baseline Structure — U.S. Parent / Israeli Subsidiary / No Legacy IP Transfer
🇺🇸 U.S. INC (Parent)
🇮🇱 Israel LTD (Subsidiary)
5. Evidence Required for New U.S. IP Ownership
The position that 'new IP belongs to the U.S.' should be supported with contemporaneous evidence showing the new IP was actually developed by or for the U.S. entity, rather than merely assigned to it after being developed in Israel.
| Evidence | Why it matters |
|---|---|
| Founder employment or consulting agreement with U.S. entity | Shows who the developer works for and which company controls the work. |
| Invention assignment to U.S. entity | Assigns U.S.-created inventions, software, designs, and related rights to the U.S. company. |
| Board approvals | Shows formal corporate ownership decisions and timing. |
| U.S. payroll or consulting payments | Shows economic substance and who bears development costs. |
| U.S. expense records | Shows which entity paid for tools, cloud, materials, subcontractors, prototypes, technical resources. |
| Repository and technical records | Git commits, design files, notebooks, tickets, test logs, metadata show who created what and when. |
| Clean separation of legacy and new IP | Helps avoid a claim that U.S. IP is merely derivative of Israeli IP without proper license or compensation. |
| Intercompany services agreement | Defines the Israeli entity's role if Israeli personnel contribute to new U.S. development. |
| Transfer-pricing file | Supports the economics of cost-plus, royalty, cost sharing, or other intercompany pricing. |
| Commercial evidence | Customer contracts, U.S. market strategy, product ownership, regulatory work, management decisions. |
6. Tax FAR Analysis: Functions, Assets, Risks and Restrictions
A FAR analysis is the backbone of the transfer-pricing position. It maps which entity performs value-driving functions, which entity owns or uses key assets, and which entity assumes and controls business risks. The allocation of profit should follow that economic profile.
| Element | Questions to answer | Implication for Tehiru |
|---|---|---|
| Functions | Who performs R&D, architecture, software development, systems design, testing, QA, product management, customer development, sales, fundraising, regulatory work, manufacturing oversight, IP protection? | If Israel performs routine R&D under U.S. direction, cost-plus may be supportable. If Israel performs entrepreneurial DEMPE functions, Israel needs more than routine compensation. |
| Assets | Who owns legacy IP, new IP, patents, software, designs, know-how, data, domain names, prototypes, capital equipment, customer contracts, technical documentation? | If legacy IP remains in Israel, the U.S. entity likely needs a license for commercialization. If new U.S. IP is claimed, the U.S. entity must own the relevant contracts and records. |
| Risks | Who controls and bears R&D risk, product failure risk, market risk, funding risk, warranty risk, regulatory risk, customer risk, IP infringement risk? | A company cannot normally earn residual returns merely because a contract says it bears risk. It must have substance, decision-making authority, and financial capacity. |
| Restrictions | Are there IIA grants, defense controls, university rights, customer restrictions, investor consents, transfer limits, or tax ruling conditions? | Restrictions can prevent or limit IP transfer and may affect valuation, licensing terms, and entity roles. |
| DEMPE | Development, Enhancement, Maintenance, Protection, and Exploitation of intangibles. | DEMPE analysis is especially important for technology IP. The entity performing or controlling DEMPE functions generally needs appropriate return. |
Practical transfer-pricing models to evaluate
| Model | When used | Tax result | Comment |
|---|---|---|---|
| Cost-plus Israel R&D services | Israel performs routine or limited-risk R&D services for U.S. parent. | Israel earns cost plus an arm's-length markup; U.S. owns new IP if it controls risks and bears costs. | Often preferred if U.S. is intended to own new IP and Israel is not the entrepreneurial owner. |
| Israel licenses legacy IP to U.S. | U.S. needs to commercialize products using Israeli legacy IP. | U.S. pays royalty to Israel; Israel retains ownership of legacy IP. | Useful alternative to outright IP sale; royalty rate needs support. |
| Cost sharing / platform contribution | U.S. and Israel both develop and exploit IP in defined territories or fields. | Requires formal cost-sharing rules, buy-in/platform contribution analysis, high documentation burden. | Potentially powerful but complex; not a default early-stage solution. |
| Profit split | Both entities perform unique and valuable contributions that cannot be benchmarked easily. | Residual profit is split based on relative contributions. | May be relevant if both Israel and U.S. materially drive IP value. |
| Outright IP sale | Commercial necessity requires U.S. ownership of all IP. | Israel recognizes sale proceeds / gain based on arm's-length IP value. | Highest tax and valuation friction; generally avoid unless required. |
7. Split IP: Useful Only if the Split Is Technically Real
A split-IP model can be useful, but it must be technically and legally defensible. It should not be a label applied after the fact.
| Question | Required answer |
|---|---|
| What exactly is legacy Israeli IP? | Patents, inventions, software, designs, algorithms, trade secrets, data, know-how, technical drawings, engineering test results, and product architecture created before U.S. activity. |
| What exactly is new U.S. IP? | Separately documented inventions, improvements, software, designs, or know-how created after the U.S. entity starts real activity. |
| Is U.S. IP dependent on Israeli IP? | If yes, the U.S. entity may need a license from the Israeli company. |
| Who performs DEMPE functions? | Development, enhancement, maintenance, protection, exploitation should be mapped by entity and by time period. |
| Who bears cost and risk? | U.S., Israel, or both. The answer should match contracts, bank payments, payroll, board minutes, day-to-day conduct. |
| Who can commercially exploit the product? | Define field, territory, exclusivity, sublicense rights, customer contracts, revenue ownership. |
| What intercompany license exists? | Exclusive or non-exclusive, territory, field, royalty, sublicensing, term, improvements, termination, audit rights, ownership of derivative works. |
8. U.S. Investor Benefit: QSBS Planning
QSBS treatment can be a major reason U.S. investors prefer investing in a U.S. C-Corp. For eligible non-corporate holders, IRC Section 1202 can exclude part or all of the gain on a sale of qualified small business stock, subject to holding period, issuer, asset, active business, redemption, and other requirements.
| Requirement / benefit | Planning point |
|---|---|
| Issuer | Stock must be issued by a domestic C corporation that satisfies the qualified small business rules. |
| Original issuance | Investor generally must acquire stock at original issue directly from the corporation for cash, property other than stock, or services. |
| Gross asset limit | For stock acquired after the 2025 effective date in current Section 1202, the issuer generally must not exceed $75M of aggregate gross assets before and immediately after issuance. Older issuances may be subject to the prior $50M threshold. |
| Holding period | Current Section 1202 provides tiered benefits for certain post-2025 acquisitions: 50% exclusion after 3 years, 75% after 4 years, 100% after 5 years. Older QSBS generally required more than 5 years for the full post-2010 100% exclusion. |
| Gain cap | For certain post-2025 acquisitions, per-issuer dollar cap is generally $15M or 10x basis, whichever is greater. Older stock may be subject to the prior $10M cap. |
| Active business | At least 80% by value of assets must be used in active qualified trades or businesses during substantially all of the holder's holding period. |
| Excluded businesses | Certain service, finance, banking, insurance, leasing, farming, extractive, hotel, restaurant, and similar businesses are excluded. A technology product / aerospace systems business may be eligible, but counsel should confirm facts. |
| Redemptions | Certain stock redemptions around the time of issuance can disqualify stock. Avoid repurchases unless counsel confirms QSBS impact. |
| Documentation | Investors often request QSBS representations, annual status letters, board records, cap history, records of aggregate gross assets. |
Application to Tehiru
- New cash investors into the U.S. C-Corp are the cleanest QSBS planning case, assuming all Section 1202 requirements are met when their stock is issued and during the holding period.
- Existing SAFE investors who invested in the Israeli company should not be promised QSBS without a dedicated analysis. An Israeli SAFE is not stock of a U.S. C-Corp. A later exchange or re-papering may not preserve prior holding period.
- Founder shares received in exchange for Israeli company stock may be problematic for QSBS because Section 1202 generally favors original issuance for cash, services, or property other than stock.
- Contributing Israeli IP or other property to the U.S. company to support QSBS could create the exact Israeli IP transfer problem the company is trying to avoid.
- The U.S. parent should maintain a QSBS support file from day one.
- Investor communications should say 'intended to qualify as QSBS' rather than guaranteeing QSBS status.
9. Israel Law for the Encouragement of Capital Investments — PTE Track
The Law for the Encouragement of Capital Investments can be highly relevant if the Israeli company owns technology IP and derives qualifying technology income from that IP. The Preferred Technological Enterprise (PTE) track can reduce Israeli tax rates on qualifying income if detailed statutory requirements are met.
| Topic | Why it matters for Tehiru |
|---|---|
| Standard Israeli corporate tax baseline | Israel's standard corporate tax rate is generally 23% for 2026, before any special incentive regime. |
| PTE reduced rates | For qualifying PTE income, reduced corporate tax rates may apply — commonly 12% outside Development Area A and 7.5% in Development Area A, subject to detailed conditions. |
| Nexus approach | Reduced rates generally apply only to the portion of income connected to IP developed in Israel, based on detailed nexus rules. |
| Qualifying income | May include income from preferred intangible assets, software-based services, products using preferred intangible assets, certain royalties, and limited R&D services. |
| Eligibility tests | Technology activity, R&D expense thresholds, R&D employee metrics, revenue/employee growth tests, venture investment criteria, Innovation Authority approval, group revenue thresholds. |
| Dividends | Dividend withholding may be reduced in some foreign corporate ownership structures, subject to conditions and treaties. |
| IP sale to related foreign company | Certain reduced capital-gains rates may be available only in narrow circumstances, often subject to Innovation Authority approval. |
| Interaction with IP migration | Keeping Israeli-developed IP in Israel may preserve PTE benefits and support an Israeli residual return. Moving IP to the U.S. can trigger tax, valuation, ruling, and benefit-loss issues. |
| Ruling strategy | PTE status can be relevant to Israeli ruling practice for post-acquisition IP transfers and conversion of an Israeli company into an R&D service provider. |
10. Valuation, DLOM, and the '80% of Company Value' Issue
The consultant comment that transferred IP may represent ~80% of company value should be treated as a valuation risk marker, not a fixed rule. For an early-stage technology company with limited physical assets, limited revenue, and a long R&D history, tax authorities may argue that most enterprise value is embedded in IP and know-how.
The prior $14M post-money valuation should not automatically be treated as current fair market value. A current valuation should consider cash remaining, burn, technical progress, customer traction, market conditions, SAFE economics, liquidation preferences, control versus minority interests, transfer restrictions, and the valuation purpose.
| DLOM point | Planning implication |
|---|---|
| Where DLOM can help | Valuing private-company common stock, minority interests, founder transfers, SAFE exchanges, share-level reorganizations, gift/estate planning, 409A common-stock valuations. |
| Where DLOM may not help | A direct sale of IP or asset transfer may not receive an equity-level DLOM. Asset-level IP valuation focuses on income, relief-from-royalty, cost, market, DEMPE, expected returns. |
| Key drivers | Expected time to liquidity, transfer restrictions, lack of public market, company stage, revenue, profitability, runway, volatility, control rights, liquidation preferences, investor rights. |
| Risk of overuse | Unsupported DLOM can be challenged. It should not be a plug number used only to reduce tax. It must be supported by a qualified valuation report. |
| Interaction with DLOC | DLOM is different from Discount for Lack of Control. If both used, the valuation firm should explain sequencing and avoid double counting. |
| Interaction with 409A | Treasury Reg 1.409A-1 expressly lists DLOM as one factor that may be considered in a reasonable valuation method for private stock. |
| Interaction with Israeli IP issue | If the tax authority views the transaction as an IP asset transfer, DLOM may be less powerful than in an equity transfer. The legal form and valuation subject matter are critical. |
11. U.S. 15-Year Amortization: Helpful but Not Decisive
If the U.S. entity actually acquires amortizable intangible property with tax basis in a respected transaction, the U.S. may be able to amortize certain acquired intangibles over 15 years under IRC Section 197. This benefit should be modeled but should not drive the decision to migrate Israeli IP.
Reasons this does not solve the problem
- It does not eliminate Israeli tax on an IP transfer.
- It does not solve the valuation dispute over the Israeli IP sale price.
- It may not apply to self-created intangibles or related-party transfers as management expects.
- It may create U.S. deductions over time while causing an immediate Israeli tax cost.
- It does not address Innovation Authority or contractual restrictions.
12. U.S. Company Options and 409A
Before granting options, the board should adopt an equity incentive plan and obtain a defensible 409A valuation of the U.S. company's common stock. Options should generally be granted with an exercise price at least equal to FMV on the grant date.
| Topic | Action point |
|---|---|
| When to obtain valuation | After U.S. parent cap and structure are set, before any option grants, and after any material event (financing, IP transfer, major commercial contract, M&A discussions, product milestone, major change in outlook). |
| Refresh cycle | A 409A is commonly refreshed at least annually, sooner after a material event. Treasury Reg 1.409A-1 treats a valuation more than 12 months old as unreasonable for later use. |
| Safe harbor | An independent appraisal dated no more than 12 months before the grant can create a presumption of reasonableness, subject to IRS rebuttal. |
| Valuation factors | Tangible and intangible assets, present value of future cash flows, market comparables, recent arm's-length transactions, control premiums, DLOM, other relevant factors. |
| Common vs preferred | Preferred financing price is not automatically the common stock FMV. The 409A should allocate enterprise value across share classes and rights. |
| ISOs vs NSOs | Employees may receive ISOs if statutory requirements are met; consultants/advisors/non-employees generally receive NSOs. |
| Board process | Board approval should specify recipient, shares, vesting, exercise price, plan, grant date, option type. No backdating. |
| Existing Israeli personnel | If Israeli employees/consultants receive U.S. parent options, coordinate Israeli tax treatment, trustee arrangements, withholding, securities rules, employer obligations with Israeli counsel. |
| QSBS interaction | Shares acquired on option exercise may potentially qualify as QSBS if Section 1202 requirements are met, but holding period generally depends on when stock is actually acquired. Do not assume the option grant date starts QSBS holding period. |
| Post-flip timing | Do not issue broad option grants before the reverse merger / flip and 409A are complete unless counsel approves sequencing. |
13. Structuring Alternatives
| Option | Best when | Pros | Cons |
|---|---|---|---|
| A. U.S. parent acquires Israeli company; no IP transfer | U.S. VC readiness needed without triggering Israeli IP transfer tax. | Clean U.S. investment story; Israeli IP remains where created; future ruling remains available; QSBS planning for new U.S. investors may be possible. | Requires intercompany agreements, investor consents, transfer-pricing maintenance, QSBS support file, valuation analysis. |
| B. U.S. investors invest directly into Israeli company | Near-term U.S. VC structure is not critical. | Simpler tax posture; no immediate reorganization; Israeli IP remains in Israel. | Many U.S. investors prefer Delaware C-Corp; QSBS generally unavailable for Israeli company stock; future flip may still be needed. |
| C. Transfer Israeli IP to U.S. now | A major financing or acquisition requires U.S. ownership of all IP and tax cost is acceptable. | U.S. entity owns all IP; possibly simpler investor/acquirer story; possible U.S. amortization benefit if respected. | Israeli tax exposure; valuation dispute; possible grant restrictions; ruling may be needed; cash tax cost may arrive before liquidity. |
| D. Close Israel and restart in U.S. | Israeli company truly has no valuable IP, no grants, no employees, no liabilities, no investor constraints. | Simple only if the Israeli company is truly empty. | Likely risky if Israeli company owns valuable IP; liquidation can create transfer/distribution issues; may harm PTE or ruling strategy. |
| E. Split IP with license | Legacy IP is real and must remain in Israel, but U.S. needs commercialization rights and new U.S. IP ownership. | Can preserve Israeli IP while enabling U.S. market activity; supports transfer-pricing model. | Requires clear technical separation, license economics, ongoing documentation. |
14. Recommended Action Plan
Phase 1: Fact cleanup
Israeli cap table and founder ownership records; SAFE agreements, side letters, investor comms, conversion mechanics; U.S. company formation/cap records; all IP assignments from founder/employees/consultants; list of patents, code repos, designs, trade secrets, domains, data sets, technical drawings, product docs; history of R&D work (who/when/where/agreement/paying entity); any IIA/MoD/university/customer/export-control/grant restrictions; current financials (cash, burn, liabilities, debt, runway, funding needs); prior financing docs supporting the $14M post-money.
Phase 2: Create an IP and FAR map
| Israeli legacy IP | U.S. new IP |
|---|---|
| Created before U.S. activity. | Created after U.S. entity begins real activity. |
| Created by Israeli company, founder, Israeli employees, or Israeli contractors. | Created by people contracted to or employed by the U.S. entity. |
| Owned by Israeli company. | Owned by U.S. company if documented. |
| Licensed to U.S. if needed for commercialization. | May license improvements back to Israel if commercially needed. |
| Potentially eligible for Israeli PTE / nexus benefits. | Potentially supports U.S. residual profit if U.S. performs and controls key functions. |
Phase 3: Implement transaction documents
Share exchange or contribution agreement; board and shareholder approvals; SAFE exchange/conversion/investor consent docs; intercompany services agreement; IP license from Israel to U.S. (if needed); founder employment/consulting agreement with U.S. company; founder invention assignment with U.S. company; Israeli R&D services agreement (likely cost-plus); transfer-pricing memo and annual support file; QSBS support file and investor disclosure language; U.S. equity incentive plan, 409A valuation, option grant package.
Phase 4: Tax ruling, valuation, and compliance strategy
Ask Israeli tax counsel whether to seek a pre-ruling confirming no taxable IP transfer; evaluate whether a ruling is needed on the Israeli company's role as R&D/service provider; analyze Israeli PTE eligibility; prepare valuation analysis if IP may later be sold/licensed/contributed; confirm whether any grants or governmental restrictions apply; model Israeli tax cost, U.S. amortization benefit, DLOM impact, withholding, cash tax impact under each alternative; obtain U.S. tax advice on QSBS for new investors, SAFE holders, founder shares, option exercises.
15. Key Questions for Advisors
- Can the U.S. parent structure be implemented as a share-level transaction without any actual or deemed IP transfer?
- Will founder U.S. parent shares, existing SAFE investor shares, or only new investor shares have credible QSBS potential?
- How should existing Israeli SAFEs be re-papered into the U.S. structure without impairing investor economics or creating unnecessary tax issues?
- What Israeli tax ruling or pre-ruling should be obtained before the reverse merger / flip?
- Does the Israeli company qualify, or can it qualify, as a Preferred Technological Enterprise?
- Should the Israeli company license legacy IP to the U.S. entity, and if so, on what terms?
- What transfer-pricing model should apply to Israeli services: cost-plus, license royalty, cost-sharing, profit split, or another model?
- What is the defensible current valuation of the company, the Israeli shares, the U.S. parent shares, and the legacy Israeli IP?
- Can DLOM be applied, to which asset or equity interest, at what percentage, and with what supporting evidence?
- When should the 409A valuation be performed relative to the flip, financing, and option grants?
- What Israeli tax and trustee rules apply if Israeli service providers receive options in the U.S. parent?
- What ongoing reporting, withholding, and documentation obligations exist in Israel and the U.S.?
🎯 Bottom Line
Recommended path: Proceed with a U.S. parent / Israeli subsidiary structure only if it can be done without transferring Israeli legacy IP. Keep the Israeli company alive as the owner of historical IP. Use the U.S. company for future fundraising, U.S. commercialization, and properly documented new U.S. IP creation. Preserve QSBS planning for new U.S. investors, but do not guarantee QSBS for founder or existing Israeli SAFE holders without a dedicated opinion. Build the transfer-pricing and FAR file now. Evaluate Israeli PTE benefits before moving IP. Use DLOM only through a qualified valuation report. Do not grant U.S. options until the U.S. company has a valid 409A valuation and a board-approved equity plan.
📚 Selected Public Reference Points for Advisor Discussion
Counsel should verify all points against current law and Tehiru's specific facts before any transaction is implemented.
| Reference | Relevance | Link |
|---|---|---|
| IRC Section 1202 | QSBS statutory requirements, exclusion percentages, gain caps, asset limits, original issuance, active business rules. | law.cornell.edu ↗ |
| IRS Transfer Pricing overview | Section 482 and arm's-length standard for controlled transactions. | irs.gov ↗ |
| Treasury Regulation 1.482-1 | Arm's-length standard, comparability, best-method principles. | law.cornell.edu ↗ |
| OECD Transfer Pricing | Global reference for arm's-length transfer-pricing principles and functional analysis. | oecd.org ↗ |
| Israel ECIL page | General description of the Encouragement of Capital Investments Law purpose. | gov.il ↗ |
| PwC Israel incentives summary | Public summary of PTE eligibility, tax rates, dividends, qualifying income. | taxsummaries.pwc.com ↗ |
| PwC Israel corporate tax summary | Public summary of Israeli corporate tax rate and incentive regime context. | taxsummaries.pwc.com ↗ |
| IRS DLOM Job Aid | IRS valuation reference on Discount for Lack of Marketability. | irs.gov (PDF) ↗ |
| Treasury Regulation 1.409A-1 | 409A stock option rules, FMV valuation factors, safe-harbor methods, 12-month concept. | law.cornell.edu ↗ |
| IRC Section 197 / IRS Intangibles | 15-year amortization framework for acquired Section 197 intangibles. | irs.gov ↗ |